New data could revive Pfizer's Mylotarg
This article was originally published in Scrip
Executive Summary
New investigator-initiated research could help revive Pfizer's acute myeloid leukaemia (AML) treatment, Mylotarg (gemtuzumab ozogamicin), following the withdrawal of the product last year.
You may also be interested in...
Pfizer's Mylotarg Likely To Get New Orphan, Biologics Exclusivities
Return to market for leukemia drug expected to generate another orphan drug exclusivity from new indication; Mylotarg also appears on track for 12-year biologics exclusivity after being approved as BLA, rather than an NDA as it was for its initial 2000 approval.
Mylotarg Returns: US FDA Approves Pfizer's Leukemia Drug With Bonus Pediatric Indication
Agency's Oncologic Drugs Advisory Committee had only discussed gemtuzumab as a treatment for adults with acute myeloid leukemia at its July meeting, but labeling includes a pediatric claim based on a 29-patient trial; drug returns to the US market after being withdrawn in 2010 for failure to confirm clinical benefit.
Pfizer's Mylotarg Rejoins AML Market At $24,600 List Price
CD33 inhibiting drug that was yanked from the market in 2010 due to reports of veno-occlusive disease is now fully approved by the US FDA at a lower recommended dose.